FOLD
HealthcareAmicus Therapeutics, Inc. · Biotechnology · $5B
What is Amicus Therapeutics, Inc.?
Amicus Therapeutics is a Philadelphia-based biotechnology company dedicated to developing medicines for rare diseases. Its commercial and pipeline portfolio targets conditions with few or no existing treatment options, serving patients who often have limited alternatives.
Amicus generates revenue primarily through Galafold, an oral precision medicine approved for adults with Fabry disease who carry an amenable genetic variant. Beyond its commercial product, the company advances a pipeline that includes novel treatments for Pompe disease and gene therapy programs targeting rare neurological conditions such as CLN3 Batten disease and CDKL5 deficiency disorder. Collaboration agreements with institutions including Nationwide Children's Hospital and the University of Pennsylvania support its research efforts.
Amicus Therapeutics was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
- Galafold — oral precision medicine for eligible Fabry disease patients
- AT-GAA — novel enzyme replacement therapy approach for Pompe disease
- CLN3 gene therapy program for Batten disease (Phase 1/2)
- CDKL5 gene therapy targeting a rare neurological disorder
- Rare disease research collaborations with leading academic institutions
Is FOLD a Good Stock to Buy?
UQS Score rates FOLD as Below Average overall, reflecting a mixed profile where exceptional growth potential is offset by meaningful financial and risk concerns.
The Growth pillar stands out as the clearest strength in FOLD's profile, driven by Galafold's expanding commercial footprint and a pipeline with multiple rare-disease programs at various stages. The Moat pillar registers as Neutral, acknowledging the orphan-drug positioning and regulatory exclusivities that provide some competitive insulation.
The Quality and Risk pillars both score Weak, pointing to profitability challenges typical of a company still investing heavily in pipeline development. The Valuation pillar is Elevated, suggesting the market has already priced in considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does FOLD pay dividends?
No — Amicus Therapeutics, Inc. does not currently pay a dividend.
Amicus Therapeutics does not currently pay a dividend. As a rare-disease biotech with an active pipeline and ongoing clinical programs, the company directs available capital toward research, development, and commercialization efforts rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does FOLD report earnings?
Amicus Therapeutics reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have been shaped by Galafold's global rollout, while pipeline investment continues to weigh on near-term profitability. Progress on clinical milestones tends to be a key focus for investors each reporting period.
For the most recent quarter's results and guidance, visit Amicus Therapeutics' investor relations page directly.
FOLD Price History
+56.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Amicus Therapeutics, Inc.?
Based on Amicus Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
FOLD Long-term Outlook
FOLD's Strong Growth pillar reflects genuine commercial momentum behind Galafold and the potential for pipeline catalysts to expand the company's addressable market. However, the Weak Risk pillar signals that execution risk remains elevated — clinical setbacks or slower-than-expected patient uptake could materially affect the trajectory. The Elevated Valuation pillar indicates that much of the anticipated growth may already be reflected in the current share price, leaving limited margin for error.
Growth drivers
- Continued global expansion of Galafold prescriptions in Fabry disease
- Pipeline advancement in Pompe disease and gene therapy programs
- Potential new rare-disease indications supported by academic collaborations
Key risks
- Clinical trial failures or delays across multiple pipeline programs
- Elevated valuation leaving little buffer if growth disappoints
- Ongoing cash consumption from R&D before additional products reach market
FOLD vs Peers
Amicus operates in a competitive rare-disease and specialty biotech landscape alongside companies with distinct strategic profiles.
Ligand operates a royalty-based business model, collecting revenue from a broad portfolio of partnered drugs rather than funding its own commercial infrastructure.
Spyre focuses on next-generation antibody therapies for immune-mediated diseases, representing a different therapeutic area and earlier-stage risk profile.
Xenon concentrates on ion-channel biology to develop treatments for epilepsy and pain, with a pipeline built around a specialized mechanistic platform.
Frequently Asked Questions
What does Amicus Therapeutics do?
Amicus Therapeutics is a biotechnology company focused on rare diseases. Its lead commercial product, Galafold, treats eligible adults with Fabry disease. The company also advances a pipeline of enzyme replacement therapies and gene therapy programs targeting other rare conditions, including Pompe disease and neurological disorders.
Does FOLD pay dividends?
No, Amicus Therapeutics does not pay a dividend. The company reinvests available capital into its research pipeline and commercial operations. Investors seeking income from their holdings should note that no dividend distribution is currently in place.
When does FOLD report earnings?
Amicus Therapeutics reports financial results on a quarterly basis, in line with standard US-listed company practice. For the exact schedule and most recent results, check the investor relations section of the Amicus Therapeutics website.
Is FOLD a good stock to buy?
UQS Score rates FOLD as Below Average overall. The Growth pillar is Strong, reflecting commercial and pipeline momentum, but the Quality and Risk pillars are both Weak, and Valuation is Elevated. The complete pillar breakdown is available to UQS Pro members.
Is FOLD overvalued?
The UQS Valuation pillar for FOLD is rated Elevated, suggesting the current price reflects a high degree of optimism about future growth. Investors should weigh this against the execution risks inherent in a company still building out its pipeline and commercial reach.
How does FOLD compare to its competitors?
Compared to peers like Ligand Pharmaceuticals, Spyre Therapeutics, and Xenon Pharmaceuticals, Amicus is differentiated by its focus on rare metabolic and neurological diseases and its single approved commercial product. Each competitor operates with a distinct business model or therapeutic focus. The full UQS comparison is available on the platform.
What is FOLD's market cap bracket?
Amicus Therapeutics is classified as a mid-cap company. This places it in a segment of the biotech market that typically carries more liquidity than small-cap peers but may have less financial resilience than large-cap pharmaceutical companies.
Who founded Amicus Therapeutics?
Amicus Therapeutics was incorporated in 2002. Detailed founding history, including the names of original founders, is publicly available through the company's official disclosures and widely reported in biotech industry sources.
Is FOLD a long-term quality stock?
As a long-term quality indicator, FOLD's UQS profile is mixed. The Strong Growth pillar points to meaningful potential, but Weak Quality and Risk scores highlight that the company has not yet demonstrated the financial durability typically associated with high-quality long-term holdings. Pro members can view the full analysis.
What is the main competitive advantage of Amicus Therapeutics?
Amicus benefits from orphan-drug designations and regulatory exclusivities for its rare-disease products, which limit direct competition. Its focus on genetically defined patient populations — particularly those with specific Fabry disease variants — creates a targeted positioning that is difficult for generalist competitors to replicate quickly.
Is FOLD a growth stock or value stock?
Based on its UQS profile, FOLD leans toward the growth category — the Growth pillar is rated Strong, reflecting expanding commercial sales and a pipeline with multiple potential catalysts. However, the Elevated Valuation pillar suggests investors are already paying a premium for that growth potential.
Unlock Full FOLD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare FOLD against rare-disease biotech peers
- ✓See the full risk and valuation breakdown
- ✓Get the complete analyst-grade quality report
Pro Analysis
FOLD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 18, 2026 | 42.8 | 20.9 | 41.0 | 89.0 | 25.3 | 38.3 | -1.5 |
| Apr 17, 2026 | 44.3 | 20.9 | 41.0 | 89.0 | 25.3 | 47.9 | +0.1 |
| Apr 9, 2026 | 44.2 | 20.9 | 41.0 | 89.0 | 25.3 | 47.3 | +0.1 |
| Apr 2, 2026 | 44.1 | 20.9 | 41.0 | 89.0 | 25.3 | 46.9 | — |
FOLD — Pillar Breakdown
Quality
— 20.9/100 (25%)Amicus Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 89.0/100 (20%)Amicus Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 25.3/100 (15%)Amicus Therapeutics, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 38.3/100 (15%)Amicus Therapeutics, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)Amicus Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for FOLD.
Score Composition
Financial Data
More Stock Analysis
How is the FOLD UQS Score Calculated?
The UQS (Unified Quality Score) for Amicus Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Amicus Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Amicus Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.